NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee A meeting minutes

**Minutes:** Confirmed

**Date:** Tuesday 5th August 2025

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr Radha Todd (Chair) Present for all items
2. Dr James Fotheringham (Vice-chair) Present for all items
3. Richard Ballerand Present for all items
4. Dr Ian Bernstein Present for all items
5. Dr Andrew Champion Present for all items
6. Dr Patrick De Barr Present for all items
7. Dr Steve Edwards Items 1.1 to 4.2.2
8. Mario Ganau Present for all items
9. Victoria Houghton Present for all items
10. Vageesh Jain Present for all items
11. Dr Youssof Oskrochi Present for all items
12. Hugo Pedder Present for all items
13. Dr Zoe Philips Present for all items
14. Dominic Pivonka Items 1.1 to 4.2.2
15. Dr Ravi Ramessur Present for all items
16. Rajeev Shah Present for all items
17. Min Ven Teo Present for all items
18. Jaqueline Tomlinson Present for all items
19. Matthew Walton Present for all items

NICE staff (key players) present

Emily Crowe, Associate Director Items 1.1 to 4.2.2

Jeremy Powell, Project Manager Items 1.1 to 4.2.2

Caron Jones, Heath Technology Assessment Adviser Items 1.1 to 4.2.2

Alice Bell, Heath Technology Assessment Analyst Items 1.1 to 4.2.2

Ian Watson, Associate Director Items 5.1 to 5.2.2

Jennifer Upton, Project Manager Items 5.1 to 5.2.2

Zoe Charles, Heath Technology Assessment Adviser Items 5.1 to 5.2.2

Anna Willis, Heath Technology Assessment Analyst Items 5.1 to 5.2.2

External assessment group representatives present

Dwayne Boyers, Aberdeen HTA Items 1.1 to 4.1.3

David Cooper, Aberdeen HTA Items 1.1 to 4.1.3

Kate Ennis, BMJ Technology Assessment Group Items 5.1 to 5.1.3

Melina Vasileiou, BMJ Technology Assessment Group Items 5.1 to 5.1.3

Clinical, Patient & NHS England experts present

Dr Daniel Knight, Consultant cardiologist- clinical expert nominated by MSD

Items 1.1 to 4.1.3

Dr Iain Armstrong, PHA UK Chair & Nurse Consultant- clinical expert nominated by PHA UK Items 1.1 to 4.1.3

Mrs Julie Royle, Patient expert nominated by PHA UK Items 1.1 to 4.1.3

Mr Josh Howey, Patient Expert nominated by PHA UK Items 1.1 to 4.1.3

Professor Richard Russell, Clinical Reader in Respiratory Medicine/ Chest Physician – Clinical expert, nominated by Sanofi UK Items 5.1 to 5.1.3

Sarah Sleet, CEO, Asthma & Lung UK – Clinical expert, nominated by Asthma & Lung UK

Items 5.1 to 5.1.3

Richard McCabe, Patient expert, nominated by Asthma & Lung UK

Items 5.1 to 5.1.3

Dr Sanjeev Patel, Consultant Rheumatologist, Deputy Chief Clinical Information Officer – Nominated by NHSE Items 5.1 to 5.1.3

*Please note that alongside the attendees listed in this document, there were additional NICE Staff present in this meeting. These attendees were not involved in the decision making or discussions.*

## Minutes

### Introduction to the meeting

* 1. The chair, James Fotheringham, welcomed members of the committee and other attendees present to the meeting.
  2. The chair noted apologies from Patrick De Barr, Fiona McPhearson-Smith, Becky Pennington and Dr Craig Buckley.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Tuesday 1st July

### Appraisal of Sotatercept for treating pulmonary arterial hypertension [ID6163]

* 1. Part 1 – Open session
     1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Merck Sharp and Dohme.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta11103).
     3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Victoria Houghton (Lay), Mario Ganau (Clinical), and Matthew Walton (Cost).
  2. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta11103>.

### Appraisal of Chronic obstructive pulmonary disease (moderate, severe) - dupilumab [ID6235]

* 1. Part 1 – Open session
     1. The chair, Radha Todd, welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Sanofi.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta11246).
     3. The Chair led a discussion of the consultation comments presented to the committee. This information was presented to the committee by Radha Todd.
  2. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta11246>.

### Date of the next meeting

The next meeting of the Technology Appraisal Committee A will be held on Tuesday 2nd September and will start promptly at 10am.